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Abstract
Background: It is hypothesized that complex interactions between multiple environmental factors and genetic
factors are implicated in sporadic Alzheimer’s disease (AD); however, the underlying mechanisms are poorly
understood. Importantly, recent evidence reveals that expression and activity levels of the b-site APP cleaving
enzyme 1 (BACE1), which initiates amyloid-b (Ab) production, are elevated in AD brains. In this study, we
investigated a molecular mechanism by which sex and stress interactions may accelerate b-amyloidogenesis and
contribute to sporadic AD.
Results: We applied 5-day restraint stress (6 h/day) to the male and female 5XFAD transgenic mouse model of AD
at the pre-pathological stage of disease, which showed little amyloid deposition under non-stressed control
conditions. Exposure to the relatively brief behavioral stress increased levels of neurotoxic Ab42 peptides, the
b-secretase-cleaved C-terminal fragment (C99) and plaque burden in the hippocampus of female 5XFAD mice but
not in that of male 5XFAD mice. In contrast, significant changes in the parameters of b-amyloidosis were not
observed in the cerebral cortex of stressed male or female 5XFAD mice. We found that this sex- and brain
region-specific acceleration of b-amyloidosis was accounted for by elevations in BACE1 and APP levels in response
to adverse stress. Furthermore, not only BACE1 mRNA but also phosphorylation of the translation initiation factor
eIF2a (a proposed mediator of the post-transcriptional upregulation of BACE1) was elevated in the hippocampus
of stressed female 5XFAD mice.
Conclusions: Our results suggest that the higher prevalence of sporadic AD in women may be attributable to the
vulnerability of female brains (especially, the hippocampus) to stressful events, which alter APP processing to favor
the b-amyloidogenesis through the transcriptional and translational upregulation of BACE1 combined with
elevations in its substrate APP.
Background
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder and the most common cause of demen-
tia in the elderly. One of the hallmark pathologies of
AD is the senile plaque that is constituted of amyloid-b
(Ab) peptides. Although mutations in three different
genes favoring the overproduction of Ab are known to
cause early-onset familial AD (FAD) [1,2], the etiology
of sporadic AD that accounts for the majority of AD
cases remains unclear. It is hypothesized that complex
interactions between the genetic background and var-
ious environmental factors underlie sporadic AD [3,4]
and a stressful lifestyle may represent one of the impor-
tant risk factors for AD [5]. Elderly individuals prone to
psychological distress are more likely to develop AD
than those not prone to distress, and this trait is also
associated with a more rapid progression of disease
[6,7]. Consistent with the clinical observations, recent
studies demonstrated that exposure to adverse beha-
vioral stress accelerates the development of amyloid
pathology and worsens memory decline in transgenic
mouse models of AD [8-11], although the underlying
molecular mechanisms have not been investigated in
detail.
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Meanwhile, it is also known that women have a higher
risk of developing AD than do men. Although the long-
evity effect might be a factor in the preponderance of
women with AD, the sex difference in AD prevalence
remains even after age adjustment [12-14]. Interestingly,
not only the sex but also the brain region represents a
determinant of neuronal responses to stressful experi-
ence. For example, the hippocampus is a structure
highly sensitive to stressor and is enriched with gluco-
corticoid receptors [15]. Furthermore, opposite effects of
stress on hippocampal functions have been reported; an
acute stressful event facilitates learning and increases
dendritic spine density in male rats, whereas learning
and spine density deteriorate after exposure to the same
stressor in female rats [16-18]. Therefore, it is important
to determine whether and how gender and adverse
stress may interact to modify disease progression in dif-
ferent brain regions of AD transgenic mice.
The b-cleavage of amyloid precursor protein (APP) by
BACE1 (b-site APP cleaving enzyme 1) initiates the gen-
eration of neurotoxic Ab peptides. Notably, evidence is
accumulating that increased levels of cerebral BACE1
and/or APP expression may be crucial contributing fac-
tors in developing sporadic AD [19-22]. In this study,
we tested the hypothesis that behavioral stress may trig-
ger the upregulation of BACE1 and/or APP, which may
lead to differential acceleration of b-amyloidogenesis in
the hippocampus and cerebral cortex of male and
female subjects. Specifically, 5XFAD transgenic model
mice at 3 months of age, which exhibit little or only
faint amyloid pathology under normal conditions [23],
were exposed to 5-day restraint stress, and we compared
levels of BACE1, APP, its b-cleavage products and pla-
que burden between stressed and non-stressed subjects.
We clearly demonstrate that the hippocampus of female
5XFAD mice shows the dramatic acceleration of b-amy-
loidogenesis with significantly elevated levels of both
BACE1 and APP expression following the relatively brief
stress treatment, providing a molecular basis for the
higher prevalence and incidence of sporadic AD in
women. Furthermore, our results also suggest that not
only transcriptional but also translational mechanisms
through phosphorylation of eukaryotic initiation factor-
2a (eIF2a) may underlie BACE1 elevation associated
with adverse stress during AD progression.
Results
Behavioral stress accelerates Ab accumulation in 5XFAD
mice in a sex- and brain region-dependent manner
To examine the effects of adverse behavioral stress on the
pathogenesis of AD, male and female 5XFAD mice at 3
months of age, which develop little or only slight amyloid
deposition under normal conditions [23], were subjected
to 5-day restraint stress (6 h/day). Twenty-four hours
after the cessation of stress treatments, we first
performed sandwich ELISA to compare Ab levels
between stressed and non-stressed 5XFAD mouse brains
(Figure 1). The hippocampal and cortical samples were
collected separately from male and female 5XFAD mice.
The 5-day restraint stress significantly increased Ab42
levels only in the hippocampus of female 5XFAD mice [F
(1,14) = 29.00, p < 0.0001], while the other three groups
of 5XFAD brain samples showed no significant difference
in Ab42 levels between stressed and non-stressed sub-
jects (Figure 1).
To test whether the ELISA measurements of Ab42
reflected the acceleration of amyloid plaque formation, we
conducted Ab immunostaining using separate groups of
male and female 5XFAD mice with or without stress treat-
ments (Figure 2). Little or no amyloid deposition was
found in the hippocampus of non-stressed male (Figure
2A) or female (Figure 2D) 5XFAD control mice. Impor-
tantly, plaque load, as measured by percentage area occu-
pied by Ab deposits, was significantly increased by
exposure to the restraint stress in the hippocampus of
female 5XFAD mice [F(1,12) = 10.96, p = 0.0062] (Figure
2E, F) but not in that of male 5XFAD mice (Figure 2B, C).
In the cerebral cortex, non-stressed male and female
5XFAD mice exhibited faint amyloid deposition (mainly,
Figure 1 Effects of behavioral stress on Ab42 levels in the
hippocampus and cerebral cortex of 5XFAD mice. Male and
female mice were exposed to restraint stress for 6 h per day during
5 consecutive days and were sacrificed for analysis 24 h after the
last stress treatment. Levels of total Ab42 were quantified by
sandwich ELISA of guanidine extracts of hippocampal and cortical
samples and expressed in nanograms per milligram of total protein
(n = 5-8 mice per group). Note that Ab42 levels are increased
specifically in the hippocampus of stressed female 5XFAD mice as
compared with non-stressed controls (*p < 0.05). All data are
presented as mean ± SEM.
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in layer 5); however, stress treatments did not affect corti-
cal Ab burden in male or female 5XFAD mice (data not
shown). Taken together, 5-day restraint stress elevated
Ab42 concentrations (~2.7-fold), leading to the higher pla-
que load (~2.4-fold) specifically in the hippocampus of
female 5XFAD mice.
Behavioral stress elevates BACE1 and APP levels in 5XFAD
mice in a sex- and brain region-dependent manner
To address the mechanisms underlying sex- and brain
region-specific acceleration of Ab accumulation follow-
ing exposure to adverse stress in 5XFAD mice, we first
compared stress-induced changes in hippocampal
b-amyloidogenic APP processing between male and
female 5XFAD mice (Figure 3). Immunoblot analysis of
hippocampal homogenates from male (Figure 3A) and
female (Figure 3B) mice demonstrated that 5-day expo-
sure to restraint stress did not change BACE1 levels in
male 5XFAD mice (Figure 3C), whereas it increased
BACE1 expression in female 5XFAD mice (Figure 3D).
A one-way ANOVA and post-hoc Fisher’s PLSD test
revealed that BACE1 levels in the hippocampus of
stressed female 5XFAD mice were significantly higher
than those of non-stressed wild-type and 5XFAD mice
Figure 2 Effects of behavioral stress on Ab load in the hippocampus of 5XFAD mice. Mice were exposed to restraint stress for 6 h per day
during 5 consecutive days and were sacrificed for analysis 24 h after the last stress treatment. Brain sections from male (A, B) and female (D, E)
5XFAD mice were immunostained with the 6E10 anti-Ab antibody. Shown are representative photomicrographs of the hippocampus of 5XFAD
mice with (B, E) or without (A, D) stress treatments. Scale bar = 500 μm. Percentage area occupied by amyloid deposits in the hippocampus of
male (C) and female (F) 5XFAD mice was measured for quantification (n = 6-7 mice per group). Note that hippocampal plaque burden is
significantly increased in stressed female but not male 5XFAD mice as compared with non-stressed controls (* p < 0.05). All data are presented
as mean ± SEM.
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Figure 3 Effects of behavioral stress on APP processing in the hippocampus of 5XFAD mice. Mice were exposed to restraint stress for 6 h
per day during 5 consecutive days and were sacrificed for analysis 24 h after the last stress treatment. Representative immunoblots of protein
extracts from hippocampal homogenates of male (A) and female (B) 5XFAD mice with and without exposure to stress are shown along with
those of non-stressed wild-type controls. Intensities of immunoreactive bands were quantified by phosphorimaging and were expressed as
percentage of wild-type controls for BACE1 (C, D) or as percentage of non-stressed 5XFAD levels for full-length APP (E, F) and C99 (G, H). Data
are presented as mean ± SEM for male (C, E, G) and female (D, F, H) subjects (n = 4-9 mice per group). #p < 0.05 vs. non-stressed wild-type
controls, *p < 0.05 vs. non-stressed 5XFAD mice.
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[F(2,18) = 10.40, p = 0.001]. Transgene-derived overex-
pression of human APP in 5XFAD mice was several
folds relative to endogenous levels of APP detected in
wild-type controls (Figure 3A, B). Similar to changes in
BACE1 levels, the stress treatment significantly elevated
levels of hippocampal full-length APP in female 5XFAD
mice [F(1,14) = 32.47, p < 0.0001] (Figure 3F) but not in
male 5XFAD mice (Figure 3E). In consequence, levels of
the b-secretase-cleaved C-terminal fragment (C99) were
not altered in the hippocampus of stressed male 5XFAD
mice (Figure 3G), while C99 levels were dramatically
elevated (~5-fold) in that of stressed female 5XFAD
mice compared with non-stressed 5XFAD controls [F
(1,14) = 67.21, p < 0.0001] (Figure 3H). We also tested
how the same 5-day restraint stress would affect APP
processing in the cerebral cortex of male and female
5XFAD mice. In contrast to changes observed in the
hippocampus, the adverse behavioral stress did not
significantly affect cortical BACE1 or full-length APP
levels in male or female 5XFAD mice (data not shown).
Collectively, 5-day exposure to restraint stress induced a
marked increase of C99 levels, which was accompanied
by significant elevations in both BACE1 and APP
expression, specifically in the hippocampus of female
5XFAD mice consistent with the significantly increased
Ab42 concentrations and plaque burden (Figures 1
and 2).
Transcriptional and translational mechanisms underlie
sex- and brain region-dependent BACE1 elevation in
5XFAD mice following behavioral stress
Recent evidence suggests that phosphorylation of the
translation initiation factor eIF2a (phospho-eIF2a) plays
an important role in mediating the post-transcriptional
upregulation of BACE1 in sporadic AD and 5XFAD
mouse brains at advanced stages of disease that develop
massive amyloid pathology [24-26]. We first examined
whether the phospho-eIF2a pathway was involved in
the behavioral stress-induced BACE1 elevation in
5XFAD model mice (Figure 4). The baseline levels of
phospho-eIF2a in non-stressed 5XFAD mice at the pre-
pathological stage were not significantly different from
those of wild-type control mice irrespective of sex or
brain regions. In parallel with changes in BACE1 expres-
sion, 5-day restraint stress significantly increased phos-
pho-eIF2a levels without affecting total eIF2a levels in
the hippocampus of female 5XFAD mice [F(2,22) =
8.70, p = 0.0016]. In contrast, the other three groups of
5XFAD brain samples showed no significant changes in
phospho-eIF2a levels between stressed and non-stressed
animals. Moreover, qPCR analysis revealed that BACE1
mRNA levels were also significantly higher in the hippo-
campus of female 5XFAD mice exposed to behavioral
stress as compared with that of non-stressed controls
[F(1,6) = 20.00, p = 0.0042] (Figure 5). Taken collec-
tively, the results clearly indicate that both transcrip-
tional and translational mechanisms through activation
of the eIF2a phosphorylation pathway underlie the
female hippocampus-specific elevation of BACE1
expression in response to behavioral stressors in the
5XFAD model.
Discussion
Very few AD cases can be attributable to genetic causes,
while the etiology of sporadic AD that constitutes the
majority of AD cases remains unclear [3,4]. Nevertheless,
most transgenic models of AD are created based on a
simple genetic association between the rare inherited
form of FAD and excessive Ab production and do not
encompass acquired characteristics [27-30]. Many non-
genetic factors including age, lifestyle (e.g., daily stress
and diets), medical history and education have been
reported to contribute to increasing the risk for AD
[31,32]. Epidemiological investigations also show gender
differences in the incidence and prevalence of AD with
females being at higher risk [12-14], although a biological
foundation for gender differences remains to be deter-
mined. In this study, we applied a relatively brief beha-
vioral stress to male and female 5XFAD transgenic
model mice at the pre-pathological stage of disease that
shows little or only faint amyloid deposition, and tested
the hypothesis that sex and stress interactions may repre-
sent a key mechanism underlying sporadic AD and ren-
dering women more prone to develop AD.
Our results clearly demonstrated that 5-day exposure
to restraint stress increased levels of Ab42 peptides, a
pathogenic Ab species that is more hydrophobic and has
the propensity to assemble into neurotoxic oligomers
and aggregates [33-35], in the hippocampus of female
5XFAD mice but not in male 5XFAD mice. Meanwhile,
the same stress treatment did not significantly affect
Ab42 levels in the cerebral cortex of male or female
5XFAD mice. Accordingly, amyloid plaque formation
was also accelerated specifically in the female 5XFAD
hippocampus following restraint stress. Interestingly, pre-
vious studies applied much longer stress treatments (e.g.,
several months of immobilization and/or isolation) to
APP transgenic mice and showed that such prolonged
stress exposures resulted in elevated Ab concentrations
and pathology in both the hippocampus and cortex with-
out distinction based on sex [8-11]. Therefore, it should
be noted that only 5-day exposure to restraint stress was
sufficient to significantly elevate levels of Ab42 and pla-
que load in 5XFAD mice in this study. Of particular
importance, such a brief stress treatment revealed that
the hippocampus of females is vulnerable and prone to
develop amyloid deposits in response to adverse beha-
vioral stressors. These findings support the idea that the
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higher prevalence of sporadic AD in women may be, at
least in part, attributable to the vulnerability of female
brain, especially the hippocampus, to stress mechanisms
that favor b-amyloidogenic processing of APP. This is
also consistent with the observation that hippocampal
Ab deposition is one of the earliest features of AD [36].
What mechanisms underlie the sex- and brain region-
specific acceleration of Ab accumulation following brief
stress exposure? Previous studies demonstrate a sex dif-
ference in stress effects and estrogens are known to
potentiate the glucocorticoid secretion under stress con-
ditions [37,38]. This mechanism may represent the key
Figure 4 Effects of behavioral stress on phospho-eIF2a levels in the hippocampus and cerebral cortex of 5XFAD mice. Male and female
mice were exposed to restraint stress for 6 h per day during 5 consecutive days and were sacrificed for analysis 24 h after the last stress
treatment. Representative immunoblots of phosphorylated eIF2a (p-eIF2a) and total eIF2a for hippocampal homogenates of female 5XFAD mice
with and without exposure to stress are shown along with those of non-stressed wild-type controls. Intensities of p-eIF2a-immunoreactive bands
were quantified by phosphorimaging and were expressed as percentage of wild-type controls (n = 3-9 mice per group). Note that p-eIF2a
levels, but not total eIF2a levels, are increased specifically in the hippocampus of stressed female 5XFAD mice as compared with non-stressed
wild-type controls (#p < 0.05) and non-stressed 5XFAD mice (*p < 0.05). All data are presented as mean ± SEM.
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component of the stress response that promotes b-amy-
loidosis more profoundly in female 5XFAD brains.
Alternatively, recent studies have started to reveal the
involvement of gender-specific molecular signaling pro-
cesses or sex chromosome gene expression in addition
to estrogen effects in causing sex differences in neuronal
function [39,40]. Further study is needed to address the
precise mechanisms including interactions between sex
hormones and different stress mediators linking with
changes in neuronal amyloidogenic processing of APP
associated with AD.
Importantly, we found that BACE1 expression was
elevated specifically in the hippocampus of stressed
female 5XFAD mice in accordance with increased levels
of Ab42 and plaque burden. It has been reported that
protein and/or activity levels of BACE1 become elevated
in brains of sporadic AD patients [19-21,41] and
5XFAD mice [26,42-44] as disease progresses into the
severer pathological stage with established amyloid pla-
ques. Recent studies including ours demonstrate that
phosphorylation of the translation initiation factor
eIF2a plays a critical role in mediating the post-tran-
scriptional upregulation of BACE1 associated with AD
[25,26]. Increases in phospho-eIF2a levels occur in
brains of sporadic AD and advanced pathological stages
of APP transgenic mice including the 5XFAD model
[24-26,45,46] and are shown to correlate with BACE1
elevation [25,26]. In the present study, baseline phos-
pho-eIF2a levels of non-stressed 5XFAD mice at the
pre-pathological stage were not significantly different
from those of wild-type control mice, while they were
increased by 5-day restraint stress exposure specifically
in the hippocampus of female 5XFAD mice in line with
BACE1 elevation. Therefore, these results suggest that
the phospho-eIF2a-dependent translational upregulation
of BACE1 in response to behavioral stressors may
represent an important molecular mechanism by which
environmental factors initiate b-amyloidogenesis before
significant Ab deposition occurs during the early phase
of sporadic AD. This hypothesis is strongly supported
by our recent observation that the increase in phospho-
eIF2a induced by Sal 003, a specific inhibitor of its
phosphatase, elevates BACE1 levels in younger 5XFAD
mice, which have not yet showed BACE1 upregulation
at basal levels concomitant with only marginal increases
in eIF2a phosphorylation [26].
In addition to the translational mechanism, transcrip-
tional control of BACE1 may also be implicated in AD
pathogenesis [47,48]. In this study, we showed the
increase of BACE1 mRNA level in the hippocampus of
stressed female 5XFAD mice compared with that of
non-stressed controls, suggesting a possibility that tran-
scriptional mechanisms may also contribute to the
BACE1 elevation associated with adverse behavioral
stress. Our results are consistent with the findings that
the promoter region of BACE1 gene contains glucocorti-
coid responsive elements [49] and that glucocorticoid
administration facilitates Ab production possibly via
increases in transcription of the BACE1 gene through
this binding site [50]. Some studies with postmortem
human brains report elevations in BACE1 mRNA levels
associated with sporadic AD [21,51], while others show
no changes in mRNA despite the increased levels of
BACE1 activity and protein [22,52-54]. Therefore, the
mechanisms underlying BACE1 elevation in the sporadic
AD brain remain controversial, which may be accounted
for by differences in complex environmental factors
mainly responsible for the disease progression. Our
mouse model study suggests that both transcriptional
and translational mechanisms may underlie BACE1 ele-
vations associated with adverse stress during the devel-
opment of AD.
Intriguingly, we also found that stress-responsive
increases in APP expression levels occurred only in the
hippocampus of female 5XFAD mice. Therefore, it
seems likely that elevations in both BACE1 and its sub-
strate APP work cooperatively to enable dramatic
increases in the intermittent b-cleaved C-terminal frag-
ment C99 and the acceleration of Ab42 production and
plaque formation in the hippocampus of female 5XFAD
mice following 5-day exposure to behavioral stress.
Given that Ab and C99 peptides are amyloidogenic and
can induce synaptic failure, neurodegeneration and
memory loss [34,55-59], behavioral stress-dependent
elevations in both b-cleavage products through BACE1
Figure 5 Effects of behavioral stress on BACE1 mRNA levels in
the hippocampus of female 5XFAD mice. Mice were exposed to
restraint stress for 6 h per day during 5 consecutive days and were
sacrificed for real-time qPCR analysis 24 h after the last stress
treatment. BACE1 mRNA levels were significantly elevated in the
hippocampus of stressed female 5XFAD mice as compared with
that of non-stressed 5XFAD controls (*p < 0.05) (n = 4 mice per
group). All data are presented as mean ± SEM.
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and APP upregulation have important implications for
the pathogenesis of sporadic AD and the progression of
neuronal dysfunction. Our findings are in agreement
with recent reports showing that exposure to stress-level
glucocorticoids (daily injections of dexamethasone for
7-21 days) elevates both BACE1 and APP levels leading
to accelerated C99 production and Ab accumulation
[50,60,61]. However, these pharmacologically induced
stress responses seem more robust than the behavioral
stress regimen applied in this study as the changes are
observed in brains of male subjects including 3xTg-AD
transgenic model mice and middle-aged wild-type mice
or rats. In any case, our present study combined with
others indicates that elevated levels of glucocorticoids
found in sporadic AD brains [62-64] may not only be a
consequence of the pathology but also play a causal
role in triggering b-amyloidogenesis through BACE1
and APP elevations during earlier stages of disease
progression.
Conclusions
Our mouse model study clearly demonstrates that the
responsiveness of brains (especially, hippocampal neu-
rons) to stress conditions, which shift APP processing
toward b-amyloidogenesis by upregulating BACE1 and
its substrate APP, represents a crucial contributing factor
in the development of sporadic AD and may account for
a mechanism underlying the increased prevalence of
women to develop AD. Moreover, our data also suggest
that transcriptional and translational mechanisms may
underlie BACE1 elevation in response to adverse stres-
sors, supporting the idea that therapeutic interventions
aimed at suppressing stress-related signaling pathways
(e.g., reduction of glucocorticoids or eIF2a phosphoryla-
tion) may be beneficial for slowing down AD progression.
Methods
Animals
We used 5XFAD transgenic mice that co-overexpress
FAD mutant forms of human APP (the Swedish muta-
tion: K670N, M671L; the Florida mutation: I716V; the
London mutation: V717I) and presenilin-1 (PS1: M146L,
L286V) transgenes under transcriptional control of the
neuron-specific mouse Thy-1 promoter (Tg6799 line)
[23,65]. 5XFAD lines (B6/SJL genetic background) were
maintained by crossing hemizygous transgenic mice with
B6/SJL F1 breeders (Taconic, Hudson, NY). 5XFAD
transgenic mice used were hemizygotes with respect to
the transgene and non-transgenic wild-type littermate
mice served as controls. Genotyping was performed by
PCR analysis of tail DNA. All experiments were done
blind with respect to the genotype of the mice, and were
conducted with the approval of the Nathan Kline Insti-
tute Animal Care and Use Committee.
Behavioral stress
Stressed 5XFAD mice were individually placed in a well-
ventilated plastic tube (Diameter: 3.8 cm) (541-RR, Plas-
Labs, Lansing, MI) and restrained for 6 h per day during
5 consecutive days. After each stress session, the mice
were returned to their cage where they were housed in
isolation with free access to food and water. Twenty-
four hours after the last exposure to restraint stress,
brain samples were collected. The timing of stress treat-
ments was arranged so that 5XFAD mice were precisely
at 3 months of age when sacrificed. Non-stressed con-
trol mice were kept group-housed in their home cage
and were sacrificed for analysis at 3 months of age.
Ab42 ELISA
Sandwich Ab ELISA was performed as described pre-
viously [66,67]. Briefly, each hemibrain sample was
extracted in 8X cold 5 M guanidine HCl plus 50 mM
Tris HCl (pH 8.0) buffer, and centrifuged at 20,000 g
for 1 h at 4°C to remove insoluble material. Final guani-
dine HCl concentrations were below 0.1 M. Protein con-
centrations were determined by a BCA protein assay kit
(Pierce, Rockford, IL). To quantitate total levels of cere-
bral Ab42, supernatant fractions were analyzed by a
well-established human Ab42 ELISA kits (KHB3441,
Invitrogen, Carlsbad, CA) according to the protocol of
the manufacturer. Optical densities at 450 nm of each
well were read on a VersaMax tunable microplate reader
(Molecular Devices, Sunnyvale, CA), and sample Ab42
concentrations were determined by comparison with the
standard curves. Ab42 concentration values were nor-
malized to total brain protein concentrations and
expressed in nanograms per milligram of total protein.
Ab immunohistochemistry
Mice were transcardially perfused with 4% paraformal-
dehyde in phosphate buffered saline (PBS) under deep
isoflurane anesthesia. The brain was removed and sec-
tioned coronally at 40 μm on a vibratome (VT1200,
Leica Microsystems, Wetzlar, Germany), and successive
sections were stored in PBS containing 0.01% sodium
azide at 4°C. Four sections per mouse were stained by
the avidin-biotin peroxidase complex method for immu-
nohistochemical analysis of amyloid deposition in the
hippocampus and cerebral cortex [66,67]. Each section
was separated by ~120 μm and taken at levels of -1.5/-
1.9 mm to bregma according to the mouse brain atlas of
Franklin and Paxinos [68]. The sections were incubated
overnight at 4°C with monoclonal anti-Ab1-16 antibody
(1:200; 6E10, Signet, Dedham, MA). The ABC kit (PK-
2200, Vector Laboratories, Burlingame, CA) was utilized
with 3,3’-diaminobenzidine tetrahydrochloride as a chro-
mogen to visualize the reaction product. The sections
were then mounted on charged slides, dehydrated in a
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series of alcohol, cleared in xylene, and covered with a
coverslip. Light microscopy was conducted on an Axios-
kop 2 microscope equipped with an AxioCaM HRc digi-
tal camera (Zeiss, Munich, Germany) for capturing
images. Semi-quantitative analysis was performed using
AxioVision imaging software with the AutoMeasure
module (Zeiss). Identified objects after thresholding
were individually inspected to confirm the object as a
plaque or not in a blinded manner. Percentage area
occupied by Ab deposits in the hippocampus and cortex
was assessed bilaterally, and the average of the indivi-
dual measurements from each mouse was calculated to
compare plaque load between the stressed and non-
stressed 5XFAD mice.
Immunoblot analysis
Hippocampal and cortical samples were taken from the
mice under deep isoflurane anesthesia and were snap-
frozen for Western blot analysis [66,67]. Each sample
was homogenized in 5 volumes of modified RIPA buffer
containing 150 mM NaCl, 50 mM Tris HCl (pH 8.0), 1
mM EDTA, 1% IGEPAL, 0.5% sodium deoxycholate,
0.1% SDS and protease/phosphatase inhibitor cocktails
(Calbiochem, La Jolla, CA), and centrifuged at 10,000 g
for 10 min to remove any insoluble material. Protein
concentrations were determined by a BCA kit (Pierce),
and 20-50 μg of protein was run on 4-12% NuPAGE
gels (Invitrogen) and transferred to nitrocellulose mem-
brane. After blocking, membranes were probed with
anti-BACE1 (1:1,000, MAB5308, Millipore, Billerica,
MA), an antibody that recognizes C-terminal epitope in
APP (1:1,000, C1/6.1, kindly provided by Dr. Paul Math-
ews, Nathan Kline Institute) to detect full-length APP/
C-terminal fragments, anti-phospho-eIF2a(Ser51)
(1:1,000, #3398, Cell Signaling Technology, Danvers,
MA), anti-eIF2a (1:1,000, #9722, Cell Signaling Technol-
ogy) or anti-b-actin (1:15,000, AC-15, Sigma, St. Louis,
MO). They were then incubated with horseradish perox-
idase-conjugated secondary IgG. Immunoblot signals
were visualized by an ECL chemiluminescence substrate
reagent kit (Pierce) and were quantified by densito-
metric scanning and image analysis using Quantity One
software (Bio-Rad Laboratories, Hercules, CA).
Real-time qPCR
qPCR was performed in triplicate on frozen hippocam-
pal samples as described previously [69,70]. TaqMan
qPCR primers were utilized for mouse BACE1 mRNA
(Mm00478671_m1, Applied Biosystems, Foster City,
CA) and the housekeeping gene glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH, Mm99999915_g1,
Applied Biosystems). Samples were assayed on a real-
time qPCR cycler (7900HT, Applied Biosystems) in
96-well optical plates covered with optical adhesive film.
Standard curves and cycle threshold were generated
using standards obtained from total mouse brain RNA.
The delta delta cycle threshold (ddCT) method was
employed to determine relative gene level differences
between stressed and non-stressed 5XFAD mice with
GAPDH qPCR products used as a control, and expres-
sion levels were presented as percentage of non-stress
controls. Negative controls consisted of the reaction
mixture without input RNA.
Statistical analysis
The significance of differences between the groups was
determined by a one-way ANOVA and post-hoc Fisher’s
PLSD tests were performed when appropriate. Data
were presented as mean ± SEM and the level of signifi-
cance was set for p value less than 0.05.
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